|
|
 |
|
 |
|
| 1 |
Ishiwata K, Suzuki S, Igarashi K, Ruike Y, Naito K, Ishida A, Deguchi-Horiuchi H, Fujimoto M, Koide H, Imamura Y, Sakamoto S, Ichikawa T, Ikeda JI, Yokote K. Characteristics of benign adrenocortical adenomas with 18F-FDG PET accumulation Eur J Endocrinol. 2021 Jun 5;185(1):155-165. doi: 10.1530/EJE-20-1459. PMID: 33960957
|
| 2 |
Sawada D, Naito S, Aoyama H, Shiohama T, Ichikawa T, Imagawa E, Miyake N, Matsumoto N, Fujii K. Remitting and exacerbating white matter lesions in leukoencephalopathy with thalamus and brainstem involvement and high lactate. Brain Dev. 2021 Aug;43(7):798-803. doi: 10.1016/j.braindev.2021.03.008. Epub 2021 May 4. PMID: 33962821.
|
| 3 |
Kamada S, Namekawa T, Ikeda K, Suzuki T, Kagawa M, Takeshita H, Yano A, Okamoto K, Ichikawa T, Horie-Inoue K, Kawakami S, Inoue S. Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma Oncogene. 2021 Jun;40(22):3899-3913. doi: 10.1038/s41388-021-01822-5. Epub 2021 May 10. PMID: 33972682
|
| 4 |
Sazuka T. Editorial Comment from Dr Sazuka to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan. Int J Urol. 2021 Aug;28(8):820-821. doi: 10.1111/iju.14597. Epub 2021 May 19. PMID: 34013556
|
| 5 |
Rii J, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Yamada Y, Maimaiti M, Ando K, Wakai K, Xu M, Imamura Y, Shindo N, Hirota T, Kaneda A, Kanai Y, Ikehara Y, Anzai N, Ichikawa T. Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor. Cancer Sci2021 Sep;112(9):3871-3883.
doi: 10.1111/cas.14991. PMID: 34050700 Epub 2021 Jul 8.
|
| 6 |
Maimaiti M, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Matsusaka K, Xu M, Ando K, Saito S, Wakai K, Imamura Y, Nakayama K, Kanai Y, Kaneda A, Ikehara Y, Ikeda JI, Anzai N, Ichikawa T. The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2 Sci Rep. 2021 Jun 1;11(1):11478. doi: 10.1038/s41598-021-90748-9. PMID: 34075107
|
| 7 |
Sato H, Kasuya G, Ishikawa H, Nomoto A, Ono T, Nakajima M, Isozaki Y, Yamamoto N, Iwai Y, Nemoto K, Ichikawa T, Tsuji H; Working Group for Genitourinary Tumors. Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer. Cancer Sci. 2021 Sep;112(9):3598-3606. doi: 10.1111/cas.15019. Epub 2021 Jul 9. PMID: 34107139; PMCID: PMC8409298.
|
| 8 |
Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M. Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study. Urol Oncol. 2021 Jun 8:S1078-1439(21)00209-X. doi:10.1016/j.urolonc.2021.05.003. Online ahead of print. PMID: 34112576
|
| 9 |
Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M; Japanese Urological Oncology Group. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. Cancer Sci. 2021 Sep;112(9):3616-3626. doi: 10.1111/cas.15038. Epub 2021 Jul 10. PMID: 34145921
|
| 10 |
Nakajima K, Mizokami A, Matsuyama H, Ichikawa T, Kaneko G, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A; PROSTAT-BSI Investigators. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study. Int J Urol. 2021 Sep;28(9):955-963. doi: 10.1111/iju.14614. Epub 2021 Jun 19. PMID: 34148264; PMCID: PMC8453930.
|
| 11 |
Oshima S, Asai S, Seki N, Minemura C, Kinoshita T, Goto Y, Kikkawa N, Moriya S, Kasamatsu A, Hanazawa T, Uzawa K. Identification of Tumor Suppressive Genes Regulated by miR-31-5p and miR-31-3p in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2021 Jun 8;22(12):6199. doi: 10.3390/ijms22126199. PMID: 34201353
|
| 12 |
Takuma Kato , Hiromi Hirama , Koji Mitsuzuka , Satoru Maruyama , Hiroshi Sasaki , Toshihiro Saito , Ryuji Matsumoto , Shinichi Sakamoto , Yasuyuki Sakai , Hiroshi Fukuhara , Yukio Naya , Hiromasa Tsukino , Isao Hara , Osamu Ogawa , Katsuyoshi Hashine , Fukuta Fumimasa , Akira Yokomizo , Yoichiro Tohi , Yoshiyuki Kakehi , Mikio Sugimoto Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN
Prostate Cancer Prostatic Dis 2021 Jul 12.doi: 10.1038/s41391-021-00422-4. Online ahead of print. PMID: 34253849
|
| 13 |
Iida K, Miyake M, Murakami K, Komiyama M, Okajima E,?Sazuka T, Nishiyama N, Yasumoto H, Kimura T, Ito A, Shiga K, Yamagishi A, Kikuchi H, Sugimoto M, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K. Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy. Int J Clin Oncol. 2021 Nov;26(11):2104-2112. doi: 10.1007/s10147-021-01988-8. Epub 2021 Jul 27.PMID:?34313904
|
| 14 |
Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Ha Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study Int J Clin Oncol 2022 Jan;27(1):194-201.
doi: 10.1007/s10147-021-02041-4. Epub 2021 Oct 2. PMID: 34599725
|
| 15 |
Kamada S, Ikeda K, Suzuki T, Sato W, Kitayama S, Kawakami S, Ichikawa T, Horie K, Inoue S. Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma Front Oncol. 2021 Nov 3;11:758503. doi: 10.3389/fonc.2021.758503. eCollection 2021. PMID: 34804954
|
| 16 |
Kato R, Kojima T,?Sazuka T, Yamamoto H, Fukuda S, Yamana K, Sugino Y, Hamamoto S, Nakaigawa N, Kabu K, Murakami H, Obara W. A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma. Anticancer Res. 2021 Dec;41(12):6199-6209. doi: 10.21873/anticanres.15439.PMID:?34848474
|
| 17 |
Sazuka T. Editorial Comment to Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy. Int J Urol. 2021 Dec 15. doi: 10.1111/iju.14770. Online ahead of print.PMID: 34908190
|
| 18 |
Xue Zhao, Shinichi Sakamoto, Maihulan Maimaiti, Naohiko Anzai, Tomohiko Ichikawa Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways Cancers (Basel) 2022 Jan 4;14(1):229. doi: 10.3390/cancers14010229.
PMID: 35008399
|
| 19 |
Yamada Y, Beltran H. The Treatment Landscape of Metastatic Prostate Cancer. Cancer Lett. 28: 20-29.2021. doi: 10.1016/j.canlet.2021.06.010.
|
| 20 |
Yamada Y, Beltran H. Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep.23.15. 2021. doi: 10.1007/s11912-020-01003-9.
|
| 21 |
Conteduca V, Hess J, Yamada Y, Ku SY, Beltran H. Epigenetics in Prostate Cancer: Clinical Implications. Transl Androl Urol: 10:3104-3116. 2021.
|
| 22 |
Zhao X, Sakamoto S, Maimaiti M, Anzai N, Ichikawa T. Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways Cancers (Basel). 2022 Jan 4;14(1):229. doi: 10.3390/cancers14010229. PMID: 35008399
|
| 23 |
Kanesaka M, Sakamoto S, Yamada Y, Rii J, Maimaiti M, Sazuka T, Imamura Y, Komiya A, Akakura K, Ikehara Y, Nakatsu H, Ichikawa T.
Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients. Prostate Int. 2021 Dec;9(4):208-214. doi: 10.1016/j.prnil.2021.06.001. Epub 2021 Jul 28. PMID: 35059359
|
| 24 |
Asai S, Koma A, Nohata N, Kinoshita T, Kikkawa N, Kato M, Minemura C, Uzawa K, Hanazawa T, Seki N.
Impact of miR-1/miR-133 Clustered miRNAs: PFN2 Facilitates Malignant Phenotypes in Head and Neck Squamous Cell Carcinoma. Biomedicines. 2022 Mar 12;10(3):663. doi: 10.3390/biomedicines10030663. PMID: 35327465
|
|
 |
|
| 1 |
Ikeyama S, Kanda S, Sakamoto S, Sakoda A, Miura K, Yoneda R, Nogi A, Ariji S, Shimoda M, Ono M, Kanda S, Yokoyama S, Takahashi K, Yokoyama Y, Hattori M.
A case of early onset cystinuria in a 4-month-old girl. CEN Case Rep. 2021 Oct 20. doi: 10.1007/s13730-021-00655-1. Online ahead of print. PMID: 34669168
|
| 2 |
Sazuka T, Fujimoto A, Sato H, Arai T, Imamura Y, Sakamoto S, Ikeda JI, Ichikawa T. Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab IJU Case Rep. 2021 Aug 16;4(6):355-358. doi: 10.1002/iju5.12347. eCollection 2021 Nov. PMID: 34755054
|
| 3 |
Arai T, Takeuchi N, Sazuka T, Sato H, Imamura Y, Sakamoto S, Komiya A, Ichikawa T. Successful treatment of metastatic bladder cancer by gemcitabine-cisplatin re-challenge after pembrolizumab IJU Case Rep 2021 Jul 20;4(6):360-362.doi: 10.1002/iju5.12348. eCollection 2021 Nov. PMID: 34755056
|
|
|
|
|
|
|
|
|
|
|
|
|
